MIRA INFORM REPORT
|
Report Date : |
23.08.2013 |
IDENTIFICATION DETAILS
|
Name : |
BEIJING LUNARSUN PHARMACEUTICAL CO., LTD. |
|
|
|
|
Registered Office : |
Room 1-C1-802, Yangguang Plaza, No. 68 Anli Road, Chaoyang District, Beijing 100101 Pr |
|
|
|
|
Country : |
China |
|
|
|
|
Financials (as on) : |
31.12.2012 |
|
|
|
|
Date of Incorporation : |
03.03.2006 |
|
|
|
|
Com. Reg. No.: |
110105009375779 |
|
|
|
|
Legal Form : |
Limited LiabilitIES Company |
|
|
|
|
Line of Business : |
Subject engaged in trading of Active Pharmaceutical Ingredients (API). |
|
|
|
|
No. of Employees : |
33 |
RATING & COMMENTS
|
MIRA’s Rating : |
B |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
Status : |
Moderate |
|
Payment Behaviour : |
No Complaints |
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail: infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – March 31st, 2013
|
Country Name |
Previous Rating (31.12.2012) |
Current Rating (31.03.2013) |
|
China |
A2 |
A2 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
CHINA - ECONOMIC OVERVIEW
Since the late 1970s China has moved from a closed,
centrally planned system to a more market-oriented one that plays a major
global role - in 2010 China became the world's largest exporter. Reforms began
with the phasing out of collectivized agriculture, and expanded to include the
gradual liberalization of prices, fiscal decentralization, increased autonomy
for state enterprises, creation of a diversified banking system, development of
stock markets, rapid growth of the private sector, and opening to foreign trade
and investment. China has implemented reforms in a gradualist fashion. In
recent years, China has renewed its support for state-owned enterprises in
sectors it considers important to "economic security," explicitly
looking to foster globally competitive national champions. After keeping its
currency tightly linked to the US dollar for years, in July 2005 China revalued
its currency by 2.1% against the US dollar and moved to an exchange rate system
that references a basket of currencies. From mid 2005 to late 2008 cumulative
appreciation of the renminbi against the US dollar was more than 20%, but the
exchange rate remained virtually pegged to the dollar from the onset of the
global financial crisis until June 2010, when Beijing allowed resumption of a
gradual appreciation. The restructuring of the economy and resulting efficiency
gains have contributed to a more than tenfold increase in GDP since 1978.
Measured on a purchasing power parity (PPP) basis that adjusts for price
differences, China in 2012 stood as the second-largest economy in the world
after the US, having surpassed Japan in 2001. The dollar values of China's
agricultural and industrial output each exceed those of the US; China is second
to the US in the value of services it produces. Still, per capita income is
below the world average. The Chinese government faces numerous economic
challenges, including: (a) reducing its high domestic savings rate and
correspondingly low domestic demand; (b) sustaining adequate job growth for
tens of millions of migrants and new entrants to the work force; (c) reducing
corruption and other economic crimes; and (d) containing environmental damage
and social strife related to the economy's rapid transformation. Economic
development has progressed further in coastal provinces than in the interior,
and by 2011 more than 250 million migrant workers and their dependents had
relocated to urban areas to find work. One consequence of population control
policy is that China is now one of the most rapidly aging countries in the
world. Deterioration in the environment - notably air pollution, soil erosion,
and the steady fall of the water table, especially in the North - is another
long-term problem. China continues to lose arable land because of erosion and
economic development. The Chinese government is seeking to add energy
production capacity from sources other than coal and oil, focusing on nuclear
and alternative energy development. In 2010-11, China faced high inflation
resulting largely from its credit-fueled stimulus program. Some tightening
measures appear to have controlled inflation, but GDP growth consequently
slowed to under 8% for 2012. An economic slowdown in Europe contributed to
China's, and is expected to further drag Chinese growth in 2013. Debt overhang
from the stimulus program, particularly among local governments, and a property
price bubble challenge policy makers currently. The government's 12th Five-Year
Plan, adopted in March 2011, emphasizes continued economic reforms and the need
to increase domestic consumption in order to make the economy less dependent on
exports in the future. However, China has made only marginal progress toward
these rebalancing goals.
Source
: CIA
COMPANY NAME AND ADDRESS
BEIJING LUNARSUN PHARMACEUTICAL co., ltd.
ROOM 1-C1-802,
YANGGUANG PLAZA, NO. 68 ANLI ROAD,
CHAOYANG DISTRICT,
BEIJING 100101 PR CHINA
TEL: 86 (0)
10-80771377/80771377-8010 FAX: 86 (0)
10-64946614
EXECUTIVE SUMMARY
INCORPORATION DATE : MAR. 3, 2006
REGISTRATION NO. : 110105009375779
REGISTERED LEGAL FORM : Limited LiabilitIES
Company
STAFF STRENGTH :
33
REGISTERED CAPITAL : CNY 5,000,000
BUSINESS LINE :
TRADING
TURNOVER :
CNY 56,760,000 (AS OF DEC. 31, 2012)
EQUITIES :
CNY
5,050,000 (AS OF DEC. 31, 2012)
PAYMENT :
AVERAGE
MARKET CONDITION : AVERAGE
FINANCIAL CONDITION : STABLE
OPERATIONAL TREND : STEADY
GENERAL REPUTATION : AVERAGE
EXCHANGE RATE :
CNY 6.13 = USD 1
Adopted abbreviations:
ANS - amount not stated
NS - not stated
SC - subject company (the company inquired by you)
NA - not available
CNY - China Yuan Renminbi
SC was registered as a limited liabilities co. at local
Administration for Industry & Commerce (AIC - The official body of issuing
and renewing business license) on Mar. 3, 2006.
Company Status: Limited
liabilities co. This form of business in PR
China is defined as a legal person. No more than fifty shareholders
contribute its registered capital jointly. Shareholders bear limited
liability to the extent of shareholding, and the co. is liable for its
debts only to extent of its total assets. The characteristics of this form
of co. are as follows: Upon the establishment of the
co., an investment certificate is issued to the each of shareholders. The board of directors is
comprised of three to thirteen members. The minimum registered capital
for a co. is CNY 30,000. Shareholders may take their
capital contributions in cash or by means of tangible assets or intangible
assets such as industrial property and non-patented technology. Cash contributed by all
shareholders must account for at least 30% of the registered capital. Existing shareholders have
pre-exemption right to purchase shares of the co. offered for sale by the
other shareholders and to subscribe for the newly increased registered
capital of the co.
SC’s registered
business scopes include technology promotion service; selling chemical products
(excluding hazardous chemicals); importing and exporting commodities and
technology.
SC is mainly
engaged in trading of Active Pharmaceutical Ingredients (API).
Mr.
Xuan Niandong has been legal
representative and chairman of SC since 2007.
SC is known
to have approx. 33 employees at present
SC
is currently operating at the above stated address, and this address houses its
operating office in the commercial zone of Beijing. Detailed information of the
premise is unspecified.
SC
also houses its R & D center in Changping District, Beijing, but the
detailed information is unspecified.
http://www.lunarsun.com.cn
The design is professional and the content is well organized. At present it is in
Chinese, English and Japanese versions.
E-mail: sales@lunarsun.com.cn
Changes
of its registered information:
|
Date of change |
Item |
Before the change |
After the change |
|
|
Company name |
Beijing Lunarsun Technology Co., Ltd. |
Beijing Lunarsun Pharmaceutical Co., Ltd. |
|
Legal representative |
Zhang Weiping |
Xuan Niandong |
|
|
Shareholdings |
Zhang Weiping 80% Wang Yu 20% |
Liu Baoquan 41% Xuan Niandong 32% Chen Yongbi 27% |
|
|
|
Shareholdings |
Liu Baoquan 41% Xuan Niandong 32% Chen Yongbi 27% |
Liu Baoquan 41% Xuan Niandong 32% Cui Dongdong 27% |
For the past two years there is no record of litigation.
MAIN SHAREHOLDERS:
Name % of Shareholding
Liu Baoquan 41
Xuan Niandong 32
Cui Dongdong 27
l Legal
representative and chairman:
Mr. Xuan Niandong , ID# 372422197612210015, born in 1976, with
university education. He is currently responsible for the overall management of
SC.
Working Experience(s):
From 2007 to present Working in SC as legal
representative and chairman.
l General manager:
Mr. Liu Baoquan , ID# 120107197204284535,
born in 1972, with university education. He is currently responsible for the
daily management of SC.
Working Experience(s):
From 2007 to present Working in SC as general manager.
l Supervisor:
============
Mr. Cui Dongdong , ID#
23030219731129563X, born in 1973.
SC is mainly
engaged in trading of Active Pharmaceutical Ingredients (API).
SC’s products
mainly include: API, Adefovir Dipivoxil, Agomelatine, pharmaceutical
intermediates, basic chemicals, formulation, etc.
SC sources its
materials 90% from domestic market, and 10% from overseas market. SC sells 50%
of its products in domestic market, and 50% to overseas market.
The buying terms of SC include Check, T/T, L/C and Credit of 30-60 days.
The payment terms of SC include Check, T/T, L/C and Credit of 30-60 days.
Note:
SC’s management declined to release its major clients and suppliers.
SC
is not known to have any subsidiary at present.
Overall payment appraisal:
( ) Excellent (
) Good (X) Average (
) Fair ( ) Poor
( ) Not yet determined
The appraisal serves as a reference to reveal SC's payments habits and
ability to pay. It is based on the 3
weighed factors: Trade payment
experience (through current enquiry with SC's suppliers), our delinquent
payment and our debt collection record concerning SC.
Trade payment experience: SC refused to release any information of
its suppliers and the trade reference was not available.
Delinquent
payment record: None in our database.
Debt collection record: No overdue amount owed by SC was placed to us for
collection within the last 6 years.
Bank of China
Beijing Anli Road Sub-branch
AC#:
322056024674
Relationship:
Normal
Balance Sheet
Unit: CNY’000
|
|
As of Dec. 31,
2011 |
As of Dec. 31,
2012 |
|
Cash & bank |
4,694 |
2,260 |
|
Notes receivable
|
0 |
0 |
|
Inventory |
91 |
50 |
|
Accounts
receivable |
1,831 |
5,310 |
|
Advances to
suppliers |
2,433 |
4,470 |
|
Other accounts receivable
|
52 |
320 |
|
Deferred
expenses |
469 |
0 |
|
Drawback
receivable |
1,527 |
0 |
|
Other current
assets |
6,300 |
2,880 |
|
|
----------------- |
----------------- |
|
Current assets |
17,397 |
15,290 |
|
Fixed assets net
value |
3,212 |
3,350 |
|
Project under
construction |
0 |
0 |
|
Long term
investment |
0 |
0 |
|
Long-term
prepaid expenses |
0 |
0 |
|
Project
materials |
0 |
0 |
|
Intangible and
other assets |
0 |
0 |
|
|
------------------ |
------------------ |
|
Total assets |
20,609 |
18,640 |
|
|
============= |
============= |
|
Short loans |
0 |
0 |
|
Notes payable |
0 |
0 |
|
Accounts payable
|
6,774 |
4,790 |
|
Advances from
clients |
6,836 |
6,170 |
|
Accrued payroll |
0 |
0 |
|
Welfare payable |
0 |
0 |
|
Taxes payable |
104 |
130 |
|
Surcharge payable |
0 |
0 |
|
Other accounts
payable |
2,003 |
2,000 |
|
Other current
liabilities |
0 |
500 |
|
Interest payable |
0 |
0 |
|
|
------------------ |
------------------ |
|
Current
liabilities |
15,717 |
13,590 |
|
Long-term
liabilities |
0 |
0 |
|
|
------------------ |
------------------ |
|
Total
liabilities |
15,717 |
13,590 |
|
Equities |
4,892 |
5,050 |
|
|
------------------ |
------------------ |
|
Total
liabilities & equities |
20,609 |
18,640 |
|
|
============= |
============= |
Income Statement
Unit: CNY’000
|
|
As of Dec. 31,
2011 |
As of Dec. 31, 2012 |
|
Turnover |
63,330 |
56,760 |
|
Cost of goods sold |
50,600 |
46,880 |
|
Taxes and additional of main operations |
57 |
60 |
|
Other business
profit |
453 |
0 |
|
Other expenses |
6,806 |
5,980 |
|
Sales expense |
2,424 |
1,390 |
|
Management expense |
3,533 |
4,200 |
|
Finance expense |
129 |
130 |
|
Non-operating
income |
0 |
2,090 |
|
Non-operating expense |
0 |
10 |
|
Profit before
tax |
234 |
200 |
|
58 |
50 |
|
|
Profits |
176 |
150 |
Important Ratios
=============
|
|
As
of Dec. 31, 2011 |
As
of Dec. 31, 2012 |
|
*Current ratio |
1.11 |
1.13 |
|
*Quick ratio |
1.10 |
1.12 |
|
*Liabilities
to assets |
0.76 |
0.73 |
|
*Net profit
margin (%) |
0.28 |
0.26 |
|
*Return on total
assets (%) |
0.85 |
0.80 |
|
*Inventory
/Turnover ×365 |
1 day |
1 day |
|
*Accounts
receivable/Turnover ×365 |
11 days |
35 days |
|
*Turnover/Total
assets |
3.07 |
3.05 |
|
* Cost of
goods sold/Turnover |
0.80 |
0.83 |
PROFITABILITY:
AVERAGE
l The turnover of SC
appears average, but appears a declining trend.
l SC’s net profit
margin is average.
l SC’s return on
total assets is average.
l
SC’s cost of goods sold is average, comparing with
its turnover.
LIQUIDITY: AVERAGE
l
The current ratio of SC is maintained in a normal
level.
l
SC’s quick ratio is maintained in a normal level
l
The inventory of SC appears small in both years.
l
The accounts receivable of SC appears average in
both years.
l
SC has no short-term loan in both years.
l
SC’s turnover is in a fairly good level, comparing
with the size of its total assets.
LEVERAGE: AVERAGE
l
The debt ratio of SC is fairly high in 2011, and
average in 2012.
l
The risk for SC to go bankrupt is average.
Overall financial
condition of the SC: Stable.
SC is considered medium-sized in its line with stable financial
conditions.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.65.42 |
|
|
1 |
Rs.102.09 |
|
Euro |
1 |
Rs.87.32 |
INFORMATION DETAILS
|
Report
Prepared by : |
PRL |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
-- |
NB |
New Business |
-- |
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors and their relative weights (as
indicated through %) are as follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend (10%) Operational size
(10%)
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.